Keyphrases
Placebo
100%
Prospective Randomized Trial
100%
Ligand-receptor Binding
100%
Peroxisome Proliferator-activated Receptor
100%
Baboon
100%
Endometrial Explants
100%
Endometriosis
77%
Rosiglitazone
66%
Laparoscopy
44%
Endometrial Lesions
44%
Pelvis
22%
Endometrium
22%
Thiazolidinediones
22%
Lesion Types
22%
Placebo Groups
11%
Placebo-controlled
11%
Randomized Placebo-controlled Trial
11%
American Society
11%
Gonadotropin-releasing Hormone
11%
Reproductive Medicine
11%
Curettage
11%
Phosphate-buffered Saline
11%
Once a Day
11%
Relative Change
11%
Active Control
11%
Staging Laparoscopy
11%
Menstrual Cycle
11%
Start of Treatment
11%
Disease Assessment
11%
Eutopic
11%
Baboon Model
11%
Intrapelvic
11%
Primate Research
11%
Endometrial Tissue
11%
Nairobi Kenya
11%
Peritoneal Endometriosis
11%
Experimental Surgery
11%
Videolaparoscopy
11%
Endometriosis Model
11%
Ganirelix
11%
Ganirelix Acetate
11%
Medicine and Dentistry
Receptor
100%
Placebo
100%
Endometriosis
100%
Peroxisome Proliferator Activated Receptor Gamma
100%
Controlled Substance
100%
Laparoscopic Surgery
75%
Rosiglitazone
75%
Pelvis
25%
Mouth
25%
Endometrium
25%
Peroxisome Proliferator Activated Receptor
25%
Thiazolidinedione
25%
Ganirelix
25%
Curettage
12%
Biopsy Technique
12%
Placebo-Controlled Study
12%
Menstrual Cycle
12%
Phosphate Buffered Saline
12%
Disease Assessment
12%
Gonadotropin-Releasing Hormone
12%
Experimental Surgery
12%
Diseases
12%
Reproductive Medicine
12%
Pharmacology, Toxicology and Pharmaceutical Science
Placebo
100%
Receptor
100%
Peroxisome Proliferator Activated Receptor Gamma
100%
Endometriosis
100%
Controlled Substance
100%
Rosiglitazone
75%
Peroxisome Proliferator Activated Receptor
25%
Thiazolidinedione
25%
Tablet
25%
Ganirelix
25%
Diseases
25%
Phosphate Buffered Saline
12%
Placebo-Controlled Study
12%
Veterinary Science and Veterinary Medicine
Endometriosis
100%
Peroxisome Proliferator-Activated Receptor Gamma
100%
Peroxisome Proliferator-Activated Receptor
25%
Endometrium
25%
Ganirelix
25%
Pelvis
25%
GnRH Antagonist
12%